Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays

Rowe, T., Abernathy, R. A., Hu‐Primmer, J., Thompson, W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 812

Influenza vaccine: The challenge of antigenic drift

Carrat, F., & Flahault, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 704

Textbook of Influenza

(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 663

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333

Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy

Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J., Zambon, M. C. F. A., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 286

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

DONATO, S. D., Granoff, D. M., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 185

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

BEYER, W. E. P., Palache, A. M., Lüchters, G., Nauta, J. J. P., & Osterhaus, A. D. M. E. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.024 · Cited by 179

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 174

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

Gasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 128

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119

Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus

Ji, X., Ren, Z., Xu, N., Meng, L., Yu, Z., Feng, N., Sang, X., Li, S., Li, Y., Wang, T., et al. (2016) · Viruses · doi:10.3390/v8040115 · Cited by 8

Special Considerations for Vaccines and the Elderly

Saade, E., Canaday, D. H., Davidson, H. E., Han, L., & Gravenstein, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00003-3 · Cited by 8

Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice

Wu, J., Wang, F., Fang, F., Zhang, W., Chang, H., Zheng, L., & Chen, Z. (2010) · Archives of Virology · doi:10.1007/s00705-010-0860-4 · Cited by 8

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine

Cox, F., Saeland, E., Baart, M., Koldijk, M. H., Tolboom, J. T. B. M., Dekking, L., Koudstaal, W., Bengtsson, K. L., Goudsmit, J., & Radošević, K. (2015) · Virology Journal · doi:10.1186/s12985-015-0435-9 · Cited by 8

Recent developments of vaccines for older adults: Adjuvants and beyond

Pangrazzi, L., & Weinberger, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2517931 · Cited by 9

Vaccination choices for older people, looking beyond age specific approaches

Aspinall, R., & Lang, P. O. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1411197 · Cited by 7

Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design

Sasaki, E., Hamaguchi, I., & Mizukami, T. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1807936 · Cited by 7

New enhanced influenza vaccines for older Australians: what promise do they hold?

Sheridan, S. L., Patel, C., Macartney, K. K., & Cheng, A. C. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00334 · Cited by 7

Vaccination Strategies and Research Gaps in Hepatitis E Virus for Special Populations

Wang, M., Duan, B., Liu, M., Zhang, Y., Wu, F., Li, G., & Ouyang, Y. (2025) · Vaccines · doi:10.3390/vaccines13060621 · Cited by 6

Antineuraminidase Antibody Responses in Older Adults After Consecutive Vaccinations With Enhanced Influenza Vaccines: A Randomized Controlled Trial

Daulagala, P., Leung, Y. W. Y., Luk, L. L. H., Ho, F. C. S., Chu, S. H. N., Lin, J., Cheng, S. M. S., Leung, N., Eichelberger, M. C., Peiris, M. J. S., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf616 · Cited by 7

Immunogenicity and Safety of an MF59®-Adjuvanted and a Non- Adjuvanted Inactivated Subunit Influenza Vaccine in Adults Affected by Chronic Diseases

Baldo, V., & Baldovin, T. (2012) · Journal of Clinical Trials · doi:10.4172/2167-0870.1000112 · Cited by 6

Approaches in broadening the neutralizing antibody response of the influenza vaccine

Zhang, R., & Hung, I. F. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1984887 · Cited by 6

Recommendations on the use of MF59-adjuvanted trivalent influenza vaccine (Fluad®): Supplemental statement of seasonal influenza vaccine for 2011-2012

CADTH (2011) · Canada Communicable Disease Report · doi:10.14745/ccdr.v37i00a06 · Cited by 6

Vaccination in old age: Challenges and promises

Caruso, C., Aiello, A., Pawelec, G., & Ligotti, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822569-1.00020-2 · Cited by 4

Mf59 ® -Adjuvanted Seasonalinfluenza Vaccine

Puig‐Barberà, J. (2009) · Aging Health · doi:10.2217/ahe.09.35 · Cited by 4

Universal Influenza Vaccine Design: Directing the Antibody Repertoire

Cox, F., Juraszek, J., Stoop, E. J. M., & Goudsmit, J. (2016) · Future Virology · doi:10.2217/fvl-2016-0045 · Cited by 3

Adjuvant efficacy of mOMV against avian influenza virus infection in mice

Lee, B.-J., Lee, S. H., Song, M., Pascua, P. N. Q., Kwon, H.-I., Park, S.-J., Kim, E.-H., Decano, A. G., Kim, S., Lim, G., et al. (2013) · The Journal of Microbiology · doi:10.1007/s12275-013-3411-3 · Cited by 2

Inactivated and Recombinant Influenza Vaccines

Patel, M. M., Grohskopf, L. A., Sambhara, S. R., Belser, J. A., Katz, J. M., & Fry, A. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00033-5 · Cited by 2

Novel Strategies for Improved Vaccines for the Elderly: The Example of Influenza

Giudice, G. D., & Rappuoli, R. (2011) · Springer eBooks · doi:10.1007/978-3-0346-0219-8_10 · Cited by 2

MF59®: an oil-in-water adjuvant

Whitaker, J. A., Rouphael, N., & Mulligan, M. J. (2012) · doi:10.2217/ebo.11.401 · Cited by 2

Pharmacoeconomic evaluation of influenza vaccination programs in elderly in Italy

Iannazzo, S., & Sacchi, V. (2009) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v10i2.164 · Cited by 1

Swine flu vaccine adjuvants and multiple sclerosis – Is there potential for harmful effect?

Öztürk, Ş. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.01.026 · Cited by 1

Human Monoclonal Antibodies for Prophylaxis and Treatment of Influenza

Koudstaal, W., UytdeHaag, F. G. C. M., Friesen, R. H., & Goudsmit, J. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2_17 · Cited by 1

Vaccines and Vaccination Strategies for Older Adults

Weinberger, B. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_7 · Cited by 1

Learning from the First Pandemic of the Twenty-First Century

Giudice, G. D., & Rappuoli, R. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2_18

Vacunación antigripal convencional frente a la vacuna de subunidades adyuvada con MF59

Torrecilla, A., González, M. P., Rodríguez, F. G., & Fernández, J. R. (2009) · Atención Primaria · doi:10.1016/j.aprim.2009.06.008

Reincarnations of Influenza Virus and Challenges with the Development of a Robust Influenza Vaccine

R, G., & Govindaraju, K. (2013) · HAL

The Authorsʼ Reply

Parodi, V., de Florentiis, D., & Ansaldi, F. (2011) · Drugs & Aging · doi:10.2165/11592360-000000000-00000

Effects of Ageing on the Vaccination Response

Weinberger, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-43365-3_5

Optimizing Response to Vaccination in the Elderly

Boraschi, D., Rappuoli, R., & Giudice, G. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-39495-9_19

Vaccines against viral infections

McElhaney, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198701590.003.0088

Recommandations relatives au vaccin antigrippal trivalent contenant l’adjuvant MF59 (Fluad®)

(CCNI), C. C. N. D. L. (2011) · Relevé des maladies transmissibles au Canada · doi:10.14745/ccdr.v37i00a06f

Here’s what you need to know about the new flu vaccines for over-65s

Cheng, A. (2018) · doi:10.64628/aa.xu437hrj4

Immunological studies of cold-adapted influenza vaccine viruses in mice

Xue, L. (2010) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27333234

BindingDB Entry 50045319: Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

BindingDB (2016) · UC San Diego · doi:10.7270/q2js9s3s

Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2)

Fox, A., & Einav, T. (2025) · ImmPort · doi:10.21430/m39qxzfgzn

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection

Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., Icardi, G., & Durando, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.081 · Cited by 27

Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine

Palladino, G., Ferrari, A., Music, N., Settembre, E. C., & Wen, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.021 · Cited by 9

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

Durando, P., Icardi, G., & Ansaldi, F. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003724662 · Cited by 65

Research Article Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

Baldo, V., Baldovin, T., Pellegrini, M., Angiolelli, G., Majori, S., Floreani, A., Busana, M. C., Bertoncello, C., & Trivello, R. (2010)

Cross-protection against drifted influenza viruses

Orsi, A., Ansaldi, F., de Florentiis, D., Ceravolo, A., Parodi, V., Canepa, P., Coppelli, M., Icardi, G., & Durando, P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23239 · Cited by 39